India's Drug Regulator Issues Alert Over 90 Unapproved Medicines
In a significant public health development, India's Central Drugs Standard Control Organisation (CDSCO) has identified approximately 90 medicines being sold without regulatory approval. The flagged drugs include a wide range of common products such as painkillers, antibiotics, cough syrups, and vitamin supplements, raising serious concerns about patient safety and enforcement gaps in the pharmaceutical sector.
Regulatory Action and Supply Chain Concerns
The CDSCO has communicated with all state drug controllers, highlighting that multiple fixed-dose combinations (FDCs) tested in laboratories during 2025 were found to be unapproved and classified as new drugs. Many of these medicines are widely available across pharmacies, indicating a potential widespread infiltration into the supply chain. The regulator has directed states to verify approvals, investigate violations, and take strict action against manufacturers, marketers, and other stakeholders involved.
The presence of such unapproved drugs poses a serious public health risk, as emphasized by the CDSCO, which has reiterated that no drug can be manufactured or sold without prior approval under existing regulations. Time-bound action reports have been requested from state authorities to address this issue promptly.
Expert Insights on Fixed-Dose Combinations
Medical experts point out that the problem extends beyond mere regulatory non-compliance, touching on deeper issues with the use of combination drugs in India. Dr. Suranjit Chatterjee, Senior Consultant in Internal Medicine at Apollo Hospital, explained that fixed-dose combinations are often used excessively in the country, despite each drug having unique pharmacodynamics and absorption patterns.
"When mismatched drugs are combined, their effects and side effects may not align, making them potentially harmful rather than beneficial," Dr. Chatterjee stated. He added that while such combinations are marketed as reducing pill burden, the benefits are limited if the combination is irrational. For instance, drugs intended to be taken before and after meals may be combined, compromising their effectiveness.
Unlike many Western countries where individual drugs are preferred, India has seen a surge in such combinations without adequate scrutiny. Dr. Chatterjee stressed that patients are rarely equipped to judge appropriateness, placing the responsibility firmly on regulators to ensure safety.
Call for Sustained Enforcement
Public health experts have welcomed the CDSCO's move as timely but emphasize that sustained enforcement is crucial to removing unsafe or unnecessary drug combinations from the market. The convenience of a single pill should not come at the cost of safety, especially when scientific soundness is questionable.
This alert underscores the need for robust regulatory oversight and continuous monitoring to protect public health from potentially harmful medical products.
